By Fineline Cube 
RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) reported RMB 3.251 billion (USD 470 million) in 2025 revenue, a 89.36% year-over-year increase, and swung to a net profit of RMB 710 million (USD 103 million), marking its return to profitability. Growth was fueled by robust sales of its flagship assets—Tai’ai® (telitacicept) for autoimmune diseases and disitamab vedotin in oncology—both reinforced by National Reimbursement Drug List (NRDL) coverage. The company also secured a global out-licensing deal with Vor Biopharma for telitacicept, significantly boosting technology licensing income.
Financial & Operational Highlights (2025)
| Metric | Amount (RMB) | Amount (USD) | YOY Change |
|---|---|---|---|
| Total Revenue | ¥3.251B | $470M | ↑89.4% |
| Net Profit | ¥710M | $103M | Return to profitability |
| Cash & Notes | ¥1.493B | $216M | Strong liquidity |
| Commercial Teams | 900 (autoimmune) + 500 (oncology) | — | — |
| Hospital Coverage | 1,200 (Tai’ai) / 1,050 (disitamab vedotin) | — | Broad access |
The revenue surge reflects successful commercial execution and strategic reimbursement wins.
Core Product Performance
Tai’ai® (telitacicept) – Autoimmune Franchise
- Mechanism: Dual-target fusion protein inhibiting BLyS and APRIL, key cytokines in B-cell maturation
- Approved Indications:
- Systemic lupus erythematosus (SLE)
- Myasthenia gravis (MG)
- Generalized myasthenia gravis (approved May 2025)
- Reimbursement: All indications included in 2025 NRDL update
- Commercial Reach: Available in 1,200 hospitals via dedicated 900-person team
Disitamab Vedotin – Oncology Franchise
- Type: HER2-targeting antibody-drug conjugate (ADC)
- NRDL-Covered Indications:
- Locally advanced or metastatic urothelial carcinoma
- HER2-positive gastric cancer
- Hospital Access: Distributed to 1,050 hospitals
Global Licensing Milestone
- Partner: Vor Biopharma Inc. (U.S.)
- Asset: Telitacicept
- Territory: Global rights excluding Greater China
- Deal Impact: Drove substantial technology licensing revenue in 2025
- Strategic Value: First major global partnership validating RemeGen’s novel dual-cytokine inhibitor platform
This deal positions telitacicept for potential expansion into U.S. and EU autoimmune markets, where BLyS/APRIL inhibition remains a high-value therapeutic approach.
Market Positioning
RemeGen has successfully transitioned from a clinical-stage biotech to a vertically integrated commercial player:
Dual-franchise model: Balanced growth across autoimmune and oncology
Reimbursement leverage: NRDL inclusion drives volume adoption
Global ambition: Out-licensing de-risks R&D while funding internal pipeline
With strong cash reserves and expanding hospital penetration, the company is well-positioned to sustain double-digit growth through 2026–2027.
Forward‑Looking Statements
This brief contains forward-looking statements regarding revenue sustainability, market access, and partnership execution. Actual results may vary due to competitive pressures, regulatory decisions, and reimbursement policy changes.-Fineline Info & Tech